MTOR and cancer: We used the established AMPK activator, 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) (500 μM), the Akt inhibitor, wortmannin (1 μM), and the mTOR inhibitor, rapamycin (200 nM) and examined and compared their effects to the effects of CA treatment.